According to Bloomberg News, a new analysis of a Pradaxa study funded by Boehringer Ingelheim found 22 serious bleeding events that were not included in their original report.
Boehringer Ingelheim is facing more than 2,000 lawsuits involving the defective drug, a treatment used to prevent strokes in patients who suffer from atrial fibrillation, a heart-rhythm disorder. The Ingelheim, Germany-based company conducted the review after plaintiff’s attorneys revealed that patients who had experienced major bleeding and died while taking Pradaxa were not included in the original trial results.
The 18,000-patient study, known as RE-LY, was led by researchers at the Population Health Research Institute in Hamilton, Ontario. They also conducted the final review of the potentially-missed patients identified by 30 Boehringer staff members who combed through over 1,500 cases.
Pradaxa became the first alternative to warfarin, the standard of care for over five decades for preventing strokes caused by blood clots, when it was approved in 2010 by the US Food and Drug Administration.
Patients and their families contend that Boehringer executives knew Pradaxa posed a deadly risk to consumers when it received government approval, but sold the drug anyway.
Over 1,400 patients bled to death while taking the medicine through October 2, 2013, according to Andreas Clemens, an executive who oversaw the drug, during a deposition as part of the lawsuits.
Injured by Pradaxa? The Pharmaceutical Litigators at Colson Hicks Eidson Can Help
If you were harmed after taking Pradaxa, you should hold Boehringer Ingelheim accountable for their negligent actions by filing a lawsuit. Colson Hicks Eidson is very experienced in pharmaceutical litigation, and our injury attorneys remain involved in dozens of cases involving medical products.
Colson Hicks Eidson – Injury Attorneys